Irinotecan toxicity to human blood cells in vitro: relationship between various biomarkers.
Toxic effects of the antineoplastic drug irinotecan on human blood cells at concentrations of 9.0 microg/ml and 4.6 microg/ml were evaluated in vitro. Using the alkaline and neutral comet assay significantly increased levels of primary DNA damage in lymphocytes were detected. The induction of apoptosis/necrosis, as determined by a fluorescent assay, was also notably increased. Cytogenetic outcomes of the treatment were assessed by the analysis of structural chromosome aberrations and fluorescence in situ hybridization. A significantly higher incidence of chromatid breaks and complex quadriradials was observed. Painted chromosomes 1, 2 and 4 were equally involved in translocations, but only the chromosome 1 was involved in the formation of quadriradials. Sister chromatid exchange analysis was performed in parallel with the analysis of lymphocyte proliferation kinetics. The higher concentration of irinotecan caused almost seven-time increase, while the lower one caused a five-time increase of the basal sister chromatid exchange frequency, accompanied with significant lowering of the lymphocyte proliferation index. Using the cytokinesis-block micronucleus assay, a dose-dependent increase in micronucleus frequency along with the formation of nuclear buds and nucleoplasmic bridges was noticed. Inhibitory effects of irinotecan on enzyme acetylcholinesterase (AChE) were studied in erythrocytes. An IC(50) value of 5.0 x 10(-7) was established. Irinotecan was found to be strong inhibitor of the acetylcholine hydrolysis and to cause a continuous decrease of catalytic activity of AChE. The results obtained on a single donor may contribute to the understanding of irinotecan toxicity, but further in vitro and in vivo studies are essential in order to clarify remaining issues, especially on possible inter-individual variability in genotoxic responses to the drug.
Kopjar
Nevenka
N
Institute for Medical Research and Occupational Health, Zagreb, Croatia. nkopjar@imi.hr
Zeljezić
Davor
D
Vrdoljak
Ana Lucić
AL
Radić
Bozica
B
Ramić
Snjezana
S
Milić
Mirta
M
Gamulin
Marija
M
Pavlica
Vesna
V
Fucić
Aleksandra
A
D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000633:toxicity*; D017209:Apoptosis / Q000187:drug effects; D015415:Biomarkers; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000633:toxicity; D002800:Cholinesterase Inhibitors; D002900:Chromosomes, Human, 1-3 / Q000235:genetics; D002905:Chromosomes, Human, 4-5 / Q000235:genetics; D020552:Comet Assay; D020732:Cytogenetic Analysis; D004305:Dose-Response Relationship, Drug; D004912:Erythrocytes / Q000378:metabolism*; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D000077146:Irinotecan; D008214:Lymphocytes / Q000378:metabolism*; D012854:Sister Chromatid Exchange
D000972:Antineoplastic Agents, Phytogenic; D015415:Biomarkers; D002800:Cholinesterase Inhibitors; D000077146:Irinotecan; D002166:Camptothecin